Zacks: Analysts Expect Anixa Biosciences, Inc. (NASDAQ:ANIX) to Post -$0.09 Earnings Per Share

Brokerages expect Anixa Biosciences, Inc. (NASDAQ:ANIX) to announce earnings of ($0.09) per share for the current fiscal quarter, Zacks reports. Zero analysts have made estimates for Anixa Biosciences’ earnings. Anixa Biosciences reported earnings of ($0.81) per share in the same quarter last year, which would suggest a positive year over year growth rate of 88.9%. The firm is expected to announce its next quarterly earnings report on Thursday, January 20th.

According to Zacks, analysts expect that Anixa Biosciences will report full-year earnings of ($0.41) per share for the current fiscal year. For the next fiscal year, analysts forecast that the company will report earnings of ($0.41) per share. Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research firms that follow Anixa Biosciences.

Several brokerages have recently commented on ANIX. Zacks Investment Research raised Anixa Biosciences from a “sell” rating to a “hold” rating in a research note on Wednesday, November 3rd. HC Wainwright reissued a “buy” rating and set a $11.00 price objective on shares of Anixa Biosciences in a report on Monday, October 4th.

In other news, Director Lewis H. Titterton, Jr. acquired 11,000 shares of the firm’s stock in a transaction that occurred on Friday, January 7th. The stock was bought at an average cost of $3.08 per share, for a total transaction of $33,880.00. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Amit Kumar acquired 20,000 shares of the firm’s stock in a transaction that occurred on Friday, January 7th. The stock was purchased at an average price of $3.00 per share, with a total value of $60,000.00. The disclosure for this purchase can be found here. Insiders purchased 53,244 shares of company stock worth $196,661 over the last three months. 19.80% of the stock is owned by insiders.

A number of institutional investors have recently modified their holdings of ANIX. Adirondack Trust Co. bought a new position in shares of Anixa Biosciences during the 3rd quarter valued at about $33,000. Cedar Brook Financial Partners LLC purchased a new stake in Anixa Biosciences in the 3rd quarter worth about $48,000. Wealth Alliance Advisory Group LLC purchased a new stake in Anixa Biosciences in the 3rd quarter worth about $78,000. State Street Corp purchased a new position in shares of Anixa Biosciences during the second quarter worth approximately $90,000. Finally, Marshall Wace LLP purchased a new position in shares of Anixa Biosciences during the third quarter worth approximately $200,000. 22.04% of the stock is owned by institutional investors.

ANIX stock remained flat at $$3.42 during trading on Friday. The company had a trading volume of 206 shares, compared to its average volume of 132,463. The business’s fifty day simple moving average is $3.56 and its 200 day simple moving average is $4.19. Anixa Biosciences has a fifty-two week low of $2.71 and a fifty-two week high of $8.09. The firm has a market capitalization of $103.04 million, a price-to-earnings ratio of -3.05 and a beta of 1.65.

About Anixa Biosciences

Anixa Biosciences, Inc is a cancer-focused biotechnology company, which focuses on harnessing the body’s immune system in the fight against cancer. It operates through the following segments: Cancer Diagnostics, Cancer Therapeutics, and Legacy Patent Licensing Activities. Cancer Diagnostic segment develops CchekTM platform, a series of inexpensive non-invasive blood tests for the early detection of solid tumors, which is based on the body’s immune response to the presence of a malignancy.

Further Reading: What is Considered a Good Return on Equity (ROE)?

Get a free copy of the Zacks research report on Anixa Biosciences (ANIX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Anixa Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anixa Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.